CONTEMPORARY REAL-WORLD PATIENT CHARACTERISTICS, TREATMENT PATTERNS, AND CLINICAL OUTCOMES IN METASTATIC UVEAL MELANOMA IN THE UNITED STATES
Author(s)
April K.S. Salama, MD1, Cameron Oswalt, MD1, Aanan Misra, BSc2, Tiffany Kung, PharmD2, Gary Palmer, MD, MBA2, Kristin Kistler, PhD3, Tasneem Lokhandwala, PhD, MS3, Ezra Cohen, MD4, Adrienne Brackey, MS4, Chioma Amadi-Mgbenka, PhD, MPH4, Sneha Nishtala, MS4.
1Duke University, Durham, NC, USA, 2IDEAYA Biosciences, South San Francisco, CA, USA, 3Cencora, Conshohocken, PA, USA, 4Tempus AI, Chicago, IL, USA.
1Duke University, Durham, NC, USA, 2IDEAYA Biosciences, South San Francisco, CA, USA, 3Cencora, Conshohocken, PA, USA, 4Tempus AI, Chicago, IL, USA.
OBJECTIVES: Metastatic uveal melanoma (mUM) is a rare disease, but the most common adult intraocular malignancy. Limited treatment options and historically poor outcomes drive substantial unmet needs in mUM. Contemporary US real-world treatment patterns and clinical outcomes evidence are limited. This study analyzes clinical characteristics, treatment patterns, and outcomes in a US mUM cohort.
METHODS: This retrospective study used the Tempus AI deidentified, multimodal database and included adults diagnosed with mUM from 2019-2025. Analyses include clinical characteristics, treatment patterns, and outcomes across all lines. Here, patient characteristics, first-line (1L) systemic treatments, and overall survival (OS) are reported. The index date was the first mUM diagnosis for diagnosis-based analyses and treatment initiation for treatment-based analyses. OS was assessed from mUM diagnosis and from 1L initiation until death or last follow-up. Median OS and 95% confidence intervals (CI) were estimated using the Kaplan-Meier method.
RESULTS: Among 219 patients, median age at mUM diagnosis was 65 years; 52.5% were female. Median time from UM to mUM diagnosis was 37.1 months (Interquartile range [IQR] 17.5-76.9). HLA-A*02:01 status was positive in 42.0%, negative in 42.9%, and unknown in 15.1%. Metastases were liver-only in 67.6%, extrahepatic-only in 12.8%, and both in 19.6%. After mUM diagnosis, 94 patients (42.9%) received only 1L systemic therapy; mean (median) time to 1L initiation was 3.2 (1.5) months. The most common 1L regimens were ipilimumab+nivolumab (58.5%), tebentafusp (16.0%), and pembrolizumab (6.4%). Over median follow-up of 9.6 months, 65.8% died. Median OS was 9.3 months (CI 6.2-11.5) from mUM diagnosis and 6.9 months (CI 4.6-11.4) from 1L initiation.
CONCLUSIONS: In this real-world US cohort, most patients received 1L immunotherapy and survival remained poor. These results underscore the persistent unmet need in mUM and highlight the necessity for new and effective treatments. Forthcoming results will provide additional insights into the contemporary mUM landscape.
METHODS: This retrospective study used the Tempus AI deidentified, multimodal database and included adults diagnosed with mUM from 2019-2025. Analyses include clinical characteristics, treatment patterns, and outcomes across all lines. Here, patient characteristics, first-line (1L) systemic treatments, and overall survival (OS) are reported. The index date was the first mUM diagnosis for diagnosis-based analyses and treatment initiation for treatment-based analyses. OS was assessed from mUM diagnosis and from 1L initiation until death or last follow-up. Median OS and 95% confidence intervals (CI) were estimated using the Kaplan-Meier method.
RESULTS: Among 219 patients, median age at mUM diagnosis was 65 years; 52.5% were female. Median time from UM to mUM diagnosis was 37.1 months (Interquartile range [IQR] 17.5-76.9). HLA-A*02:01 status was positive in 42.0%, negative in 42.9%, and unknown in 15.1%. Metastases were liver-only in 67.6%, extrahepatic-only in 12.8%, and both in 19.6%. After mUM diagnosis, 94 patients (42.9%) received only 1L systemic therapy; mean (median) time to 1L initiation was 3.2 (1.5) months. The most common 1L regimens were ipilimumab+nivolumab (58.5%), tebentafusp (16.0%), and pembrolizumab (6.4%). Over median follow-up of 9.6 months, 65.8% died. Median OS was 9.3 months (CI 6.2-11.5) from mUM diagnosis and 6.9 months (CI 4.6-11.4) from 1L initiation.
CONCLUSIONS: In this real-world US cohort, most patients received 1L immunotherapy and survival remained poor. These results underscore the persistent unmet need in mUM and highlight the necessity for new and effective treatments. Forthcoming results will provide additional insights into the contemporary mUM landscape.
Conference/Value in Health Info
2026-11, ISPOR Europe 2026, Vienna, Austria
Value in Health, Volume 29, Issue 12S
Code
CO16
Topic
Clinical Outcomes
Topic Subcategory
Clinical Outcomes Assessment
Disease
Oncology, Rare & Orphan Diseases